Factors Affecting the Price of Wainua

The price of Wainua (eplontersen) is influenced by its status as a specialized treatment for hereditary transthyretin-mediated amyloidosis (hATTR), a rare condition that qualifies it for orphan drug designation. 

Factors Affecting the Price of Wainua

This status often involves high research and development (R&D) costs.Production expenses are elevated due to the need for sterile, preservative-free formulation in single-dose autoinjectors and strict storage requirements (2°C–8°C, with limited room-temperature stability) . 

Regulatory mandates, such as monitoring for vitamin A deficiency and long-term safety surveillance , also contribute to operational costs. Market exclusivity from its 2023 approval and the small patient population further drive pricing, reflecting the balance between innovation and niche therapeutic demand.